Skip to content
PeptideAI
Anecdotalmuscle growthrecovery

PEG-MGF

MGF with a polyethylene glycol chain bolted on so it survives in circulation for days instead of minutes, traded for the loss of any local-only action.

Also known as pegylated mechano growth factor, PEG MGF

Anecdotal — Community reports without controlled evidence. Treat the confident dosing charts accordingly.

There is essentially nothing published on pegylated MGF specifically. The evidence base is the underlying MGF preclinical literature, which is itself contested, plus general pharmacology on pegylation. Everything about dosing and duration is invented by the market.

How it works

The peptide core is identical to MGF; the PEG chain sterically shields it from peptidases and slows renal clearance, which is a well-established formulation strategy across biologics. The consequence is systemic exposure over days rather than a local spike over minutes. That is a genuine pharmacokinetic improvement but it undercuts the original rationale for MGF, which was that a very short-lived local signal at the site of mechanical damage is what mobilises satellite cells. Nobody has demonstrated which of those two profiles, if either, produces a result in humans. The PEG moiety, the degree of pegylation and the attachment site are undisclosed and vary between grey-market suppliers, so 'PEG-MGF' is not one consistent molecule.

Targets: Muscle satellite cells, Unidentified E-peptide receptor

Dosing

ProtocolDoseFrequencyRoute
Common anecdotal protocolNon-training days are often chosen so that plain MGF can be used post-workout, though there is no evidence behind that split.200 mcg – 400 mcgtwice weeklysubcutaneous
  • · Two doses per week is the standard folklore protocol, justified by the claimed multi-day half-life.

Cycling

Typically 4-6 weeks, then a break. No evidence base for any schedule.

Work out your exact syringe units →

Pharmacology

Half-life
Widely claimed at 2-3 days on the basis of pegylation generally; it has never been measured in humans for this specific product.
Onset
Not established.
Routes
subcutaneous, intramuscular
Molecule
Pegylated synthetic 24-amino-acid MGF E-domain peptide
Sequence length
24 amino acids

Handling

Diluent
Bacteriostatic water
Typical mix
1 or 2 mL
Vial sizes
2, 5 mg
Lyophilised
Fridge or freezer.
Reconstituted
Refrigerated and used within about 3-4 weeks; pegylation makes it somewhat more robust in solution than plain MGF.
Light sensitive
Yes — keep it out of the light

Mixing

A 2 mg vial in 2 mL gives 1000 mcg/mL, so 200 mcg is 20 units on a U-100 syringe.

Side effects

  • commonInjection-site reaction
  • commonUnknown long-term risk— Systemic exposure to an unvalidated growth-related peptide, with no human safety data and inconsistent product identity between suppliers.
  • uncommonLethargy after dosing— Reported anecdotally in the hours after injection.

Do not use if

  • Active malignancy.
  • Pregnancy and breastfeeding.
  • Known PEG hypersensitivity.

Combining it

  • redundantmgf — Identical peptide core; running both accomplishes nothing extra.
  • synergyigf-1-lr3 — Commonly stacked in hypertrophy protocols. The combination is folklore, not data.

What to monitor

  • · No established bloodwork. Track training performance and body composition objectively rather than by feel.

Legal status

Not approved for human use. Research-chemical status and prohibited in sport by WADA.

References

  • General reviews of pegylation and its effect on peptide half-life and immunogenicity (review)
  • Underlying preclinical MGF E-domain literature (see the MGF entry) (preclinical)

Mechanism in depth

PEG-MGF exists because someone reasoned that MGF's problem was that it degrades too fast, and that pegylation would fix it. The reasoning is defensible in the abstract and self-defeating in this specific case. The biology that made MGF interesting is that the IGF-1Ec splice variant is transiently induced in muscle by mechanical loading and damage - it is a local, short-lived, injury-linked signal that recruits precursor cells to a specific site. Pegylating it produces a long-circulating systemic agent, which is the opposite of that signal in both duration and distribution. So you have taken a molecule whose only mechanistic rationale is 'brief pulse at the damaged site' and engineered away the brevity and the locality. Beyond that, the downstream pharmacology is whatever MGF's is, which is a pro-migratory, anti-apoptotic effect on myogenic precursors and mesenchymal stem cells acting through an unidentified receptor that is explicitly not IGF1R. Pegylation also introduces its own considerations: the conjugate is a different molecule immunologically, PEG-specific antibodies are a documented phenomenon with pegylated therapeutics, and the accumulation profile depends entirely on a PEG size that no vendor discloses. There is no published characterisation of any PEG-MGF product, so two vials from two suppliers may be pharmacokinetically unrelated.

What usually goes wrong

The specific hazard of PEG-MGF over MGF is that you cannot undo a dose. A long-acting agent from an uncharacterised supplier means that if the vial is contaminated, misfolded or simply not what the label says, you are living with it for days rather than hours. Injection-site reactions that escalate over successive doses are the most commonly reported problem and are the classic signature of an immune response to a conjugate rather than local irritation - people usually push through them. The second issue is that the pegylation is undocumented: PEG size determines half-life, accumulation and immunogenicity, and no vendor states it, so 'twice weekly' as a frequency is unanchored to anything. The third is the same as for MGF - running it inside a stack and crediting it for the stack's results.

Bloodwork worth running

MarkerWhenWhy it matters
High-sensitivity CRPBaseline, then at two and six weeks.A pegylated peptide administered repeatedly is the profile most likely to generate an anti-drug or anti-PEG response, and a rising CRP alongside worsening injection-site reactions is the earliest cheap signal of that.Act if: A CRP climbing above roughly 3 mg/L on-cycle in someone clear at baseline, especially with escalating injection-site reactions, means stop.
Complete blood count with differentialBaseline and at six weeks.Eosinophilia or a rising white count alongside injection-site reactions points at a hypersensitivity response to the conjugate rather than a local irritation.Act if: New eosinophilia is a stop signal.
Serum IGF-1Baseline and at four weeks if stacked.Same reasoning as for MGF: it is almost always run inside a GH or IGF stack, and this is how you find out which compound is responsible for what you are seeing.Act if: Above the age-adjusted range means the stack needs attention.

Pharmacokinetics

Crosses blood-brain barrier
no
Accumulates
Yes — doses stack before steady state
Metabolism
Presumed proteolysis of the peptide backbone once the PEG shield is breached; the PEG moiety itself is not metabolised.
Elimination
Renal, with the rate depending on the PEG size used - which is not disclosed by any vendor.

Receptor targets

  • Unidentified MGF E-peptide receptor — Unknown, and pegylation typically reduces receptor affinity relative to the parent peptide by steric hindrance

    Presumed same pro-migratory and anti-apoptotic signalling as MGF, at unknown potency.

  • IGF-1 receptor (IGF1R) — Not a ligand

    None. As with MGF, vendor claims of IGF-1 receptor agonism do not match the published biology.

What to expect, and when

No reliable timeline exists. Injection-site reactions, when they occur, appear within hours and tend to worsen rather than habituate across successive doses, which is the pattern worth paying attention to. Nothing about a hypertrophic effect can be stated, because none has been demonstrated.

Stacking and comparisons

The near-universal practice is PEG-MGF twice weekly as the systemic base with plain MGF post-workout on training days, on top of GH or a secretagogue. This is the single least informative protocol design possible: three or four compounds changing at once, none of them individually characterised, and a long-acting agent whose exposure overlaps everything else. If you are going to run it, run it alone for six weeks and photograph and measure, or accept that you will learn nothing. The one real interaction concern is with other pegylated compounds - anti-PEG immunogenicity is cross-reactive, so stacking PEG-MGF with another pegylated product raises the chance of losing both to an immune response and of a genuine hypersensitivity reaction.

Against plain MGF, PEG-MGF is the version that abandons the mechanism it was named after. The whole point of the IGF-1Ec splice response is that it is transient and local; pegylation makes it sustained and systemic. If you find the MGF rationale persuasive you should be using MGF, and if you do not find it persuasive you should not be using either. Against genuinely pegylated therapeutics with real data behind them - the pegylated interferons, pegfilgrastim - the difference is that those disclose PEG size, have measured pharmacokinetics and have documented immunogenicity rates. PEG-MGF has none of the three. Against PEG-MGF's own marketing, which positions it as a longer-acting IGF-1 receptor agonist, the published biology says the parent peptide does not act at IGF1R at all.

Rough cost

$60–$160/month. 2 mg vials commonly 30-60 USD grey market; twice-weekly dosing at 200-400 mcg consumes roughly 1.6-3.2 mg a month. Priced above plain MGF for a modification nobody has characterised.

Genuinely uncertain

  • No pharmacokinetic data exist for any PEG-MGF product in any species. The 2-3 day half-life claim is extrapolated from pegylation in general, not measured.
  • PEG molecular weight and conjugation site are not disclosed by any vendor and almost certainly vary between suppliers, which means half-life, accumulation and immunogenicity vary too.
  • Whether pegylation preserves, reduces or abolishes activity at the unidentified MGF receptor is unknown. Pegylation commonly reduces potency through steric hindrance.
  • Anti-PEG antibody formation is a documented phenomenon with pegylated therapeutics generally but has never been assessed for this product.
  • Accumulation is marked true on the basis that a pegylated peptide dosed twice weekly with an assumed multi-day half-life would accumulate, not on measured data.
  • The sequence is marked unverified because the pegylation - the thing that distinguishes this product - is undocumented, even though the underlying peptide backbone is the same MGF-Ct24E sequence.
  • No molecular weight can be given without knowing the PEG size.

Papers